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Summary
Background.  —  Remote  monitoring  (RM)  is  increasingly  used  to  follow  up  patients  with
implantable  cardioverter-deﬁbrillators  (ICDs).  Randomized  control  trials  provide  evidence  for
the beneﬁt  of  this  intervention,  but  data  for  RM  in  daily  clinical  practice  with  multiple-brands
and unselected  patients  is  lacking.
Aims.  —  To  assess  the  effect  of  RM  on  patient  management  and  clinical  outcome  for  recipients
of ICDs  in  daily  practice.
Methods.  —  We  reviewed  ICD  recipients  followed  up  at  our  institution  in  2009  with  RM  or  with
traditional hospital  only  (HO)  follow-up.  We  looked  at  the  effect  of  RM  on  the  number  of  sched-
uled ambulatory  follow-ups  and  urgent  unscheduled  consultations,  the  time  between  onset  of
asymptomatic  events  to  clinical  intervention  and  the  clinical  effectiveness  of  all  consultations.
We also  evaluated  the  proportion  of  RM  notiﬁcations  representing  clinically  relevant  situations.
Results. —  We  included  355  patients  retrospectively  (RM:  n  =  144,  HO:  n  =  211,  76.9%  male,
60.3 ±  15.2  years  old,  50.1%  with  ICDs  for  primary  prevention  and  mean  left  ventricular  ejec-
tion fraction  35.5  ±  14.5%).  Average  follow-up  was  13.5  months.  The  RM  group  required  less
scheduled ambulatory  follow-up  consultations  (1.8  vs.  2.1/patient/year;  P  <  0.0001)  and  a  far
lower median  time  between  the  onset  of  asymptomatic  events  and  clinical  intervention  (7  vs.
76 days;  P  =  0.016).  Of  the  784  scheduled  ambulatory  follow-up  consultations  carried  out,  only
152 (19.4%)  resulted  in  therapeutic  intervention  or  ICD  reprogramming.  We  also  found  that  the
vast majority  of  RM  notiﬁcations  (61.9%)  were  of  no  clinical  relevance.
Conclusion.  —  RM  allows  early  management  of  asymptomatic  events  and  a  reduction  in  sched-
uled ambulatory  follow-up  consultations  in  daily  clinical  practice,  without  compromising  safety,
endorsing RM  as  the  new  standard  of  care  for  ICD  recipients.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  télésurveillance  des  déﬁbrillateurs  automatiques  implantables  (DAI)  se
généralise.  Les  études  randomisées  ont  démontré  son  utilité,  mais  les  données  manquent  sur
son utilisation  en  pratique  courante  avec  différentes  marques  et  des  patients  non  sélectionnés.
Objectifs.  —  Évaluer  l’apport  de  la  télésurveillance  pour  le  suivi  et  l’évolution  des  patients
appareillés  d’un  DAI  en  pratique  courante.
Méthodes.  —  Nous  avons  inclus  rétrospectivement  les  patients  appareillés  d’un  DAI  dont  la  télé-
surveillance  a  débuté  en  2009  dans  notre  centre,  suivis  par  télésurveillance  ou  suivi  hospitalier
(SH) seul.  Nous  avons  étudié  l’apport  de  la  télésurveillance  sur  le  nombre  de  consultations
programmées  et  en  urgence,  le  délai  entre  la  survenue  d’un  événement  asymptomatique  et
l’intervention  clinique  ainsi  que  la  pertinence  clinique  des  consultations  programmées.  Nous
avons également  évalué  la  proportion  d’alertes  de  télésurveillance  traduisant  un  événement
clinique pertinent.
Résultats.  —  Au  total,  355  patients  ont  été  inclus  (télésurveillance  :  n  =  144  ;  SH  :  n  =  211  ;  76,9  %
d’hommes ;  60,3  ±  15,2  ans  ;  50,1  %  de  DAI  en  prophylaxie  ;  fraction  d’éjection  ventriculaire
gauche moyenne  35,5  ±  14,5  %).  La  durée  moyenne  de  suivi  était  de  13,5  mois.  Dans  le  groupe
télésurveillance,  le  nombre  de  consultations  programmées  était  signiﬁcativement  réduit  (1,8  vs
2,1/patient/année  ;  p  <  0,0001)  ainsi  que  le  délai  médian  entre  un  événement  asymptomatique
et l’intervention  clinique  (7  vs  76  jours  ;  p  =  0,016).  Parmi  les  784  consultations  programmées,
152 (19,4  %)  seulement  ont  été  suivies  d’un  changement  de  thérapeutique  ou  de  programmation
du DAI.  La  majorité  des  notiﬁcations  de  télésurveillance  (61,9  %)  n’avait  pas  de  pertinence
clinique.
Conclusion.  —  La  télésurveillance  permet  une  prise  en  charge  précoce  des  événements  asymp-
tomatiques et  une  diminution  des  consultations  programmées,  en  pratique  courante,  sans  une
moindre sécurité  des  patients,  soutenant  son  utilisation  large  pour  les  porteurs  de  DAI.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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ackground
emote  monitoring  (RM)  is  increasingly  used  to  follow-up
atients  with  implantable  cardioverter-deﬁbrillators  (ICDs)
1,2].  Large  clinical  trials  [3—7]  have  already  demonstrated
he  safety  and  efﬁcacy  of  this  approach,  however,  most
ave  focused  on  speciﬁc  ICD  brands  and  results  might  not
e  applicable  to  other  brands.  Experiences  during  random-
zed  studies  may  differ  from  daily  practice  and  accounts  of
linical  experience  of  RM  outside  randomized  trial  protocols
re  lacking.  There  are  also  limited  data  on  the  effective-
ess  of  RM  in  the  management  of  asymptomatic  events  and
he  proportion  of  ICD  notiﬁcations  that  represent  clinically
elevant  events  is  relatively  uncharacterized.
ims
he  present  study  aimed  to  assess  the  beneﬁts  of  RM  in
aily  clinical  practice,  for  all  RM  systems.  We  sought  to
nvestigate  the  impact  of  RM  on  the  number  of  scheduled
mbulatory  follow-up  consultations  as  well  as  the  number
f  urgent  unscheduled  consultations.  We  also  looked  at  the
ffectiveness  of  RM  in  the  management  of  asymptomatic
vents  and  analysed  data  records  to  evaluate  the  proportion
f  RM  notiﬁcations  that  are  clinically  relevant.
ethods
tudy design
e  performed  a  retrospective  study  comparing  RM  versus
raditional  hospital  only  (HO)  follow-up  for  ICD  recipients.
ll  patients  implanted  with  an  ICD  in  the  year  2009  in
ur  institution  were  included  in  the  study,  regardless  their
ollow-up:  RM  or  HO.  In  addition,  patients  who  had  previ-
usly  been  implanted  with  an  ICD  that  was  subsequently
ctivated  for  RM  in  2009  were  also  included.  The  study  pop-
lation  was  then  divided  into  two  groups,  based  on  the  mode
f  follow-up:  RM  or  HO.  For  the  RM  group,  follow-up  started
t  the  time  of  RM  activation  and  for  the  HO  group,  at  the
ime  of  ICD  implantation.  Follow-up  ended  in  June  2011.
xclusion  criteria  included:  follow-up  at  another  centre,
eath  before  ﬁrst  outpatient  consultation  and  ICD  removal
efore  ﬁrst  outpatient  consultation.  All  brands  and  types  of
CD  were  included,  except  in  the  RM  group  where  no  patients
ad  Sorin® ICDs  manufactured  by  the  Sorin  Group  (Milan,
taly)  because  the  SmartviewTM RM  system  was  not  available
t  the  time  of  study.
In  the  RM  group,  patient  ICDs  were  able  to  trans-
it  two  types  of  RM  notiﬁcations:  scheduled  reports  and
M  alerts.  Scheduled  reports  were  transmitted  regularly
or  LatitudeTM (Boston  Scientiﬁc®,  Marlborough,  MA,  USA),
arelinkTM (Medtronic®,  Minneapolis,  MN,  USA)  and  MerlinTM
Saint  Jude  Medical®,  St.  Paul,  MN,  USA)  recipients  and
aily,  as  per  manufacturer  protocol,  for  Home  MonitoringTM
Biotronik®,  Berlin,  Germany)  recipients.  It  was  then  at  the
iscretion  of  the  clinician  to  invite  patients  for  ambulatory
ollow-up  consultations  based  on  the  data  in  these  reports,
ith  consultations  typically  happening  once  or  twice  a  year
nd  the  ﬁrst  consultation  occurring  usually  three  months
c
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fter  implantation.  RM  alerts,  on  the  other  hand,  were  trans-
itted  in  response  to  abnormal  events  detected  by  the  ICD
typically  for  unusual  cardiac  activity  or  ICD  dysfunction)  and
hese  would  always  trigger  urgent  clinical  review,  whether
r  not  the  patient  was  symptomatic  at  the  time  of  the  event.
t  was  left  at  the  discretion  of  the  clinician  to  deﬁne  thresh-
lds  for  alert  transmission.
For  patients  in  the  HO  group,  ambulatory  follow-up  was
cheduled  with  routine  consultations  every  six  months  irre-
pective  of  clinical  condition.  Patients  who  experienced
ymptoms  or  who  received  an  electrical  shock  from  their
CD  could  also  request  additional  urgent  consultations.  The
ain  difference  for  patients  in  this  group  was  that  there
as  no  mechanism  for  an  asymptomatic  event  to  be  brought
o  the  attention  of  the  clinician  before  the  next  scheduled
mbulatory  follow-up  consultation,  which  could  potentially
ut  the  patient’s  life  at  risk,  particularly  in  the  context  of
CD  dysfunction.
ata collection
ata  was  collected  retrospectively  from  implantation
ecords,  ambulatory  follow-up  notes  and  hospitalisation
eports.  RM  data  was  extracted  from  the  RM  database  at
ur  centre  and  from  RM  databanks  online.  RM  notiﬁcations
ere  classiﬁed  either  as  reports  or  alerts,  the  former  being
outine  transmissions  and  the  latter  being  in  response  to
bnormal  events  detected  by  the  ICD,  either  from  abnormal
ardiac  activity  or  ICD  dysfunction.
Events  recorded  in  both  the  RM  and  HO  groups  included:
pisodes  of  arrhythmia  (supraventricular  or  sustained  ven-
ricular  arrhythmias,  irrespective  of  whether  these  triggered
CD  therapy  or  not);  inappropriate  triggering  of  therapy
shock  delivery  or  antitachycardia  pacing);  device  related
vents  (elective  ICD  replacement  indicator,  device  reset);
ead  related  events  (noise,  impedance,  pacing  and  sensing
hreshold  issues  as  well  as  lead  perforation)  and  ICD  pro-
ramming  issues  (oversensing,  undersensing,  pacemaker
e-entrant  tachycardia,  loss  of  cardiac  resynchronization
herapy  [CRT]  or  phrenic  nerve  stimulation).  Inappropriate
herapies  secondary  to  supraventricular  arrhythmias  were
ot  considered  as  separate  events  and  heart  failure  alerts
mean  ventricular  rate,  percentage  of  CRT,  premature  ven-
ricular  contractions  per  hour,  OptiVol® [Medtronic  Inc.])
ere  reported  but  not  considered  in  our  analysis  as  their
elevance  and  clinical  consequences  have  not  yet  been  fully
alidated.
For  both  RM  and  HO  groups,  events  were  deﬁned  as  symp-
omatic  in  cases  resulting  in  ICD  shock  delivery  or  if  the
atient  requested  an  urgent  consultation  for  which  they
ere  seen  the  same  day,  otherwise,  they  were  deﬁned
s  asymptomatic.  For  instance,  if  a  clinician  requested
n  urgent  clinical  review  following  an  RM  alert,  this  was
eﬁned  as  asymptomatic  so  long  as  the  patient  had  not
xperienced  any  symptoms  and  their  ICD  had  not  delivered
 therapeutic  shock.  Patients  experiencing  asymptomatic
vents  in  the  HO  group  would  typically  be  diagnosed  at
he  next  routine  ambulatory  follow-up  consultation.  Out-
omes  of  each  asymptomatic  event  were  recorded  for  both
roups.  Some  resulted  in  intervention,  such  as  ambula-
ory  ICD  reprogramming,  changes  in  medication  regime  or
cheduling  of  invasive  procedures  on  the  ICD  and  some  did
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quite  some  time  later.  This  data  is  shown  in  Fig.  1  and
Table  2.Remote  monitoring  of  patients  with  implantable  cardioverte
not.  For  asymptomatic  events  resulting  in  intervention,  the
time  between  the  event  onset  and  intervention  was  evalu-
ated  and  recorded.
Endpoints
Our  goals  were:
• to assess  the  time  between  onset  of  asymptomatic  events
detected  by  ICD  and  clinical  intervention,  for  cases  where
intervention  was  required;
• to  investigate  the  impact  of  RM  on  the  number  of
scheduled  ambulatory  follow-up  consultations  and  urgent
unscheduled  consultations;
• to  investigate  the  outcome  of  scheduled  ambulatory
follow-up  consultations  for  patients  in  the  RM  and  HO
groups  and;
• to  assess  the  clinical  relevance  of  RM  notiﬁcations.
Statistical analysis
Statistical  analysis  was  performed  using  SAS  software  (ver-
sion  9.2,  SAS  Institute  Inc.,  Cary,  North  Carolina).  Continuous
variables  were  expressed  in  terms  of  their  mean  and
standard  deviation  values  in  cases  where  they  followed
a  normal  distribution  and  in  terms  of  their  median  and
interquartile  range  in  cases  where  they  did  not.  Qualita-
tive  variables  were  expressed  in  terms  of  frequency  and
percentage.  Comparisons  between  groups  were  performed
using  the  2 and  Fisher  exact  tests  for  qualitative  data,  and
nonparametric  Wilcoxon  test  for  quantitative  data  with  cal-
culation  of  exact  P  values.  A  P-value  <  0.05  was  considered
statistically  signiﬁcant.
Results
Study population
Out  of  the  478  eligible  patients,  123  were  excluded
for  one  or  more  of  the  following  reasons:  follow-up  at
another  centre  (n  =  109),  ICD  removal  before  ﬁrst  outpatient
consultation  (heart  transplantation:  n  =  1;  device  infection:
n  =  1),  death  before  ﬁrst  outpatient  consultation  (cardio-
genic  shock:  n  =  1)  and  missing  data  (n  =  11,  in  cases  where
ambulatory  follow-up  notes  or  hospitalisation  reports  were
missing).  Data  from  the  remaining  355  patients  was  ana-
lysed  (RM:  n  =  144;  HO:  n  =  211).  Baseline  characteristics  of
the  study  population  are  summarized  in  Table  1.  The  mean
overall  follow-up  time  was  13.5  months,  with  a  median  of
363  days  and  IQR  of  [268—436]  for  the  RM  group  vs.  460  days
and  [330—589]  for  the  HO  group;  P  <  0.0001,  the  difference
between  these  ﬁgures  being  a  result  of  the  delay  between
ICD  implantation  and  RM  activation  (median  89  days  IQR
[2—301]).
Time  from  onset  of  asymptomatic  events  to  clinical
intervention
A  total  of  164  events  were  detected  by  ICDs  in  the  RM
and  HO  groups  during  this  study,  of  which  124  (75.6%)  were
asymptomatic.  Sixty-nine  (55.6%)  of  these  resulted  in  clin-
ical  intervention  (RM:  n  =  21;  HO:  n  =  48).  The  time  from
event  onset  to  clinical  intervention  was  only  reported  in
F
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7  (53.6%)  cases  (RM:  n  =  12;  HO:  n  =  25).  For  the  remain-
ng  cases,  missing  information  meant  we  were  unable
o  evaluate  this  time  accurately,  however,  it  was  noted
hat  the  majority  of  these  event  transmissions  were  for
ecurrent  episodes  of  sustained  supraventricular  arrhyth-
ia.
Asymptomatic  events  requiring  clinical  intervention
ere:  ventricular  arrhythmia  (RM:  n  =  3;  HO:  n  =  13),
upraventricular  arrhythmia  (RM:  n  =  4;  HO:  n  =  6),  lead
ysfunction  (RM:  n  =  3;  HO:  n  = 1),  elective  replacement
ndicator  (RM:  n  =  1),  ventricular  over/undersensing  (RM:
 =  1;  HO:  n  =  4)  and  loss  of  CRT  (HO:  n  =  1).  Speciﬁc  lead
ysfunctions  detected  in  the  RM  group  were:  lead  frac-
ure  with  oversensing  of  noise  (n  =  1),  lead  fracture  with
ncreased  impedance  (n  =  1)  and  lead  perforation  of  the
yocardium  associated  with  an  appreciable  loss  of  ven-
ricular  threshold  sensing  (n  =  1).  Following  transmission
f  RM  alerts,  these  3  asymptomatic  patients  were  con-
acted  for  urgent  clinical  review.  Asymptomatic  events
ere  recorded  for  3  further  patients  receiving  inappropri-
te  antitachycardia  pacing  in  response  to  supraventricular
rrhythmias,  all  of  which  triggered  RM  alerts  and  urgent
linical  review.
In the  RM  gro-2up,  clinical  interventions  resulting  from
symptomatic  events  were:  ICD  replacement  (n  =  3),  ICD
eprogramming  (n  =  6)  and  changes  in  medication  regime
n  =  8).  For  the  HO  group,  clinical  interventions  result-
ng  from  asymptomatic  events  were:  ICD  reprogramming
n  =  13),  changes  in  medication  regime  (n  =  12),  urgent  hospi-
alisation  for  lead  testing  under  general  anaesthesia  (n  =  1),
lective  ablation  therapy  for  ventricular  tachycardia  (n  =  1)
nd  elective  cardiac  stress  testing  (n  =  1).  As  would  be
xpected,  the  median  time  from  onset  of  asymptomatic
vents  to  clinical  intervention  was  markedly  less  in  the  RM
roup  compared  with  the  HO  group  (7  vs.  76  days;  P  =  0.016),
s  asymptomatic  events  in  the  HO  group  would  only  come
o  the  attention  of  the  clinician  at  the  next  scheduled
mbulatory  follow-up  consultation,  which  in  some  cases  wasigure 1. Time from onset of events detected by implantable
ardioverter-deﬁbrillator (ICD) to clinical intervention, in cases
here patients were asymptomatic but required intervention.
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Table  1  Baseline  characteristics  of  the  study  population.
RM  group(n =  144)  HO  group(n =  211)  P
Age  —  years  57.6  ±  14.8  62.2  ±  15.2  <  0.01
Male  gender  —  n  (%)  118  (82)  155  (73)  0.06
Left  ventricular  ejection  fraction  —  %  34.4  ±  14.6  36.3  ±  14.4  0.23
NYHA  functional  class  —  n  (%)  0.36
I-II  116  (87.2)  170  (82.9)
III-IV  17  (12.8)  35  (17.1)
Ischemic  heart  disease  —  n  (%)  85  (59.0)  107  (50.7)  0.13
Comorbidities  —  n  (%)
Diabetes  mellitus 38  (26.8) 50  (23.7) 0.54
Hypertension  59  (41.3)  88  (41.7)  0.93
Chronic  kidney  disease  13  (9.1)  30  (14.2)  0.14
History  of  stroke  12  (8.4)  21  (10.0)  0.62
Atrial  ﬁbrillation  or  ﬂutter  35  (24.3)  84  (39.8)  <  0.01
Patients  receiving  ICD  for  secondary  prevention  —  n  (%) 72  (50.0)  105  (49.8)  0.97
Primary  events  prompting  ICD  implantation  —  n  (%)  0.95
SCD  due  to  VF  or  sustained  VT  42  (58.4)  66  (62.8)
Syncope  with  inducible  sustained  VT  13  (18.1)  17  (16.2)
SCD  without  documented  arrhythmia  7  (9.7)  9  (8.6)
Syncope  in  high-risk  cardiomyopathy  4  (5.6)  6  (5.7)
Syncope  and  low  LVEF  6  (8.3)  6  (5.7)
ICD  brand  —  n  (%)  <  0.0001
Biotronik  75  (52.1)  11  (5.2)
Boston  Scientiﬁc  5  (3.5)  64  (30.3)
Medtronic  54  (37.5)  33  (15.6)
Sorin  0  59  (28.0)
St  Jude  Medical  10  (6.9)  44  (20.9)
ICD  type  —  n  (%)
Single  chamber 69  (47.9) 68  (32.2) <  0.01
Dual  chamber 50  (34.7) 83  (39.3)  0.43
CRT 25  (17.4) 60  (28.4) 0.02
Medications  —  n  (%)
Beta-blocker  131  (90.9)  191  (90.5)  0.69
ACE-inhibitor  or  angiotensin-antagonist  123  (85.4)  177  (83.9)  0.54
Platelet  agglutination  inhibitor  97  (68.8)  132  (63.2)  0.28
Anticoagulant  46  (32.6)  74  (35.4)  0.59
Antialdosterone  44  (31.2)  60  (28.7)  0.62
Amiodarone  21  (14.9)  41  (19.6)  0.26
Digoxin  9  (6.4)  9  (4.3)  0.39
Diuretics  72  (50.0)  121  (57.3)  0.19
ACE: angiotensin-converting enzyme; CRT: cardiac resynchronization therapy; ICD: implantable cardioverter-deﬁbrillator; LVEF: left
ventricular ejection fraction; NYHA: New York Heart Association; VF: ventricular ﬁbrillation; SCD: sudden cardiac death; VT: ventricular
tachycardia. Continuous variables are expressed as mean ± SD.
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bmpact  of  RM  on  the  number  of  scheduled
mbulatory  follow-up  consultations  and  urgent
nscheduled consultationshe  median  number  of  ambulatory  follow-up  consultations
or  patients  in  the  RM  group  was  15%  less  than  in  the  HO
roup  (1.8  vs.  2.1/patient/year;  P  <  0.0001),  as  indicated
P
a
0
Hn  Table  3.  In  contrast,  there  was  no  signiﬁcant  difference
n  the  median  number  of  urgent  unscheduled  consultations
etween  RM  and  HO  groups  (0.12  vs.  0.08/patient/year; =  0.30).  For  the  RM  group,  the  number  of  alerts  for
symptomatic  events  prompting  urgent  clinical  review  was
.06/patient/year.  Patients  sustaining  similar  events  in  the
O  group  would  not  seek  clinical  review,  as  they  were
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Table  2  Events  detected  by  implantable  cardioverter-deﬁbrillator  (ICD)  and  their  outcome.
Patient  status
and  group
No.  of
events  (n
patients)
No.  of  urgent
consultations
Urgent  consultations
per
patient—year  —  mean
(SD)
No.  of
clinical
interventions
(n  patients)
Time  from  event
onset  to  clinical
intervention-
median  days  [IQR]
Symptomatic
RM  10  (10)  8  0.06  (±  0.24)  8  (8)  3.5  [1—75]a
HO  30  (20)  16  0.08  (±  0.39)
P  =  0.5
15  (13)  5  [2—7]a
P  =  1
Asymptomatic
RM  37  (32)  7  0.06  (±  0.36)  21  (19)  7  [3—40.5]a
HO  87  (63)  —  —  48  (39)  75.7  [19—120]a
P  =  0.016
a Figures based on reduced data set as onset of asymptomatic events was not always reported in the medical notes. See text for further
details.
Table  3  Outcome  of  scheduled  ambulatory  follow-up  consultations.
No.  of  patients  No.  of
consultations
Consultations  per
patient-year  median  [IQR]
Proportion  resulting  in  no  change  in
clinical  management
RM  144  235  1.78  [1.24—2.39]  80.7%
HO  211  549  2.10  [1.82—2.76]
01
80.4%
P =  0.93
F
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asymptomatic,  and  so  would  only  come  to  the  attention
of  the  clinician  at  the  next  routine  ambulatory  follow-up
consultation.
Outcome  of  scheduled  ambulatory  follow-up
consultations
Of  the  784  ambulatory  visits  scheduled  for  HO  and  RM
patients  during  the  study  follow-up,  only  152  (19.4%)
resulted  in  either  a  change  in  medication  regime,  ICD  repro-
gramming  or  ICD  replacement.  The  remainder  resulted  in  no
change  of  clinical  management.  The  proportion  of  consulta-
tions  not  resulting  in  any  change  did  not  differ  signiﬁcantly
between  the  RM  and  HO  groups  (80.7%  vs.  80.4%;  P  =  0.93)
as  shown  in  Table  3.
Clinical  relevance  of  RM  notiﬁcations
A  total  of  729  notiﬁcations  were  received  from  patients
during  RM  follow-up  (3.3/patient/year).  Furthermore,  451
(2.04/patient/year)  of  these  (61.9%)  were  either  ﬁrst
transmission  reports  following  RM  activation,  scheduled
transmissions  not  associated  with  any  event,  patient  trig-
gered  transmissions  not  associated  with  any  event  or  repeat
transmissions  for  reports  that  had  not  been  received  by
the  databank  web  servers  on  time.  The  remaining  278
(1.26/patient/year)  notiﬁcations  were  alerts  to  events
detected  by  the  ICD:  n  =  23  (8%)  for  ICD  or  lead  failure,  n  =  95
(34%)  for  ventricular  tachycardia/ﬁbrillation,  n  =  63  (23%)  for
supraventricular  tachycardia,  n  =  82  (30%)  for  heart  failure
and  n  =  15  (5%)  reminders  for  previous  notiﬁcations  (Fig.  2).
Of  these  278  alerts,  35  (12.6%)  led  to  clinical  intervention
(0.16/patient/year).  Seven  alerts  (2.5%)  were  triggered  by
T
m
pigure 2. Distribution of remote monitoring (RM) alerts.
otentially  harmful  events  where  patients  almost  certainly
eneﬁtted  from  early  detection  and  urgent  consultation.  Of
hese,  3  were  in  patients  who  sustained  inappropriate  anti-
achycardia  pacing  and  3  were  in  patients  who  sustained
ead  dysfunction.  The  ﬁnal  alert  was  a  repeat  transmission
or  one  of  the  patients  with  lead  dysfunction  who  generated
wo  alerts  before  urgent  clinical  review.
iscussionhe  present  study  provides  data  on  the  impact  of  ICD  remote
onitoring  in  daily  clinical  practice.  The  choice  to  include
atients  implanted  in  2009  offered  us  the  unique  opportunity
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o  compare  RM  and  HO  follow-up,  as  patients  in  our  centre
re  no  longer  managed  with  HO  follow-up.  Our  main  ﬁndings
ere:
ICD  remote  monitoring  allows  early  management  of
asymptomatic  clinical  events;
RM  signiﬁcantly  reduces  the  number  of  ambulatory  follow-
up  consultations,  without  signiﬁcantly  increasing  the
number  of  urgent  unscheduled  consultations;
the  vast  majority  of  scheduled  ambulatory  consultations
appear  unnecessary  and;
the  proportion  of  RM  alerts  resulting  in  clinical  interven-
tion  is  low.
One  might  argue  that  RM  does  not  have  any  impact  on
he  management  of  symptomatic  events  since  patients  with
ymptoms  usually  request  urgent  consultation  of  their  own
ccord.  The  advantage  of  RM,  therefore,  is  in  the  early
etection  of  asymptomatic  events  as  this  allows  clinicians  to
ntervene  before  symptoms  arise.  In  the  present  study,  RM
ramatically  reduced  the  median  time,  by  69  days,  from  the
nset  of  asymptomatic  events  to  clinical  intervention.  This
as  potentially  of  great  beneﬁt  for  the  three  patients  who
ustained  lead  dysfunction  and  who  might  otherwise  have
eceived  inappropriate  shock  therapy.  Instead,  they  were
alled  to  hospital  for  ICD  deactivation  and  lead  replace-
ent  before  any  harm  was  done.  Some  ICDs  can  produce
arning  signals,  such  as  auditory  alarms  or  vibration  alerts,
n  response  to  signiﬁcant  events  and  these  were  activated
herever  possible,  but  despite  this  the  time  to  clinical  inter-
ention  was  still  lower  in  the  RM  group.  The  median  delay
rom  asymptomatic  event  onset  to  clinical  intervention  of
 days  in  the  RM  group  might  appear  long,  however,  it  not
nly  takes  account  of  patients  called  for  urgent  review,  typ-
cally  for  lead  failure,  but  also  patients  that  did  not  require
rgent  consultation,  typically  in  cases  of  asymptomatic  ven-
ricular  tachycardia  treated  with  antitachycardia  pacing.
ur  team  previously  demonstrated  that  RM  follow-up  allows
arly  and  reliable  detection  of  ICD  lead  failure  without
equiring  patient  intervention  [8]  and  the  current  results  are
n  line  with  previous  studies  [3—7,9],  supporting  the  view
hat  these  results  are  applicable  to  daily  clinical  practice.
Numerous  studies  have  reported  a  reduction  of  inappro-
riate  shocks  with  RM  [3,5,8,10]  and  the  ECOST  [6]  study
lso  demonstrated  that  ICD  lifespan  is  increased  because
he  condenser  does  not  need  to  charge  so  many  times,
hich  results  in  a  76%  reduction  in  energy  consumption.
arly  detection  of  supraventricular  arrhythmias  could  allow
arlier  ICD  reprogramming  to  avoid  inappropriate  shocks
nd  earlier  introduction  of  anticoagulant  therapy  where
equired.  Here,  RM  allowed  the  diagnosis  of  new  onset  atrial
brillation  and  early  use  of  anticoagulant  therapy  in  one
atient  as  well  as  early  ICD  reprogramming  in  two  further
atients  following  detection  of  inappropriate  antitachy-
ardia  pacing  secondary  to  episodes  of  supraventricular
rrhythmias.  RM  also  enabled  the  early  diagnosis  of  T-wave
versensing  in  one  patient  (inappropriate  antitachycardia
acing  delivery),  which  prompted  swift  ICD  reprogramming
n  order  to  avoid  shock  delivery.The  RM  group  required  15%  less  scheduled  ambulatory
ollow-up  consultations  than  the  HO  group,  without  a  sig-
iﬁcant  increase  in  the  number  of  urgent  unscheduled
onsultations.  The  proportion  of  consultations  carried  out
p
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or  the  RM  group  that  were  unscheduled  was  6.7%  com-
ared  with  3.8%  in  the  HO  group,  indicating  that  RM  patients
equire  more  ﬂexibility  in  their  overall  management,  even
hough  the  overall  number  of  consultations  they  require
s  less.  Less  than  one  in  ﬁve  scheduled  consultations  in
his  study  resulted  in  either  therapeutic  intervention  or
CD  reprogramming,  suggesting  that  with  reﬁnements  in
election  criteria,  it  may  be  possible  to  further  reduce
he  overall  number  of  consultations  without  compromising
atient  safety.  This  would  result  in  a  signiﬁcant  reduction  in
orkload  for  cardiac  rhythm  specialists  as  well  as  an  overall
eduction  in  healthcare  costs.
Most  RM  notiﬁcations  (62%)  were  routine  reports  with  no
linical  relevance,  the  precise  proportion  being  dependent
n  ICD  brand.  These  results  emphasize  the  importance  of  ﬁl-
ering  notiﬁcations  appropriately  so  that  only  relevant  alerts
re  reviewed  by  clinicians.  In  our  centre,  a trained  engineer
as  responsible  for  the  management  of  our  RM  notiﬁcation
atabase,  tracking  alert-related  actions  and  tracking  the
ime  burden  that  RM  management  placed  on  clinicians  and
urses.  Specially  trained  nurses  would  bring  clinical  alerts
o  the  attention  of  the  cardiologist  and  manage  administra-
ive  notiﬁcations  and  transmission  failures  themselves.  From
010  onwards,  protocols  were  implemented  that  allowed
etter  ﬁltering  of  clinical  alerts  by  nurses,  thus  reducing  the
ime  burden  of  RM  management  on  cardiologists.  We  envis-
ge  software  algorithms  taking  over  this  role  more  and  more
n  the  future  towards  the  goal  of  completely  automating  RM
anagement.
tudy limitations
his  study  was  monocentric  so  institutional  bias  cannot  be
xcluded.  It  was  also  retrospective  and  therefore  subject  to
 number  of  limitations.  In  particular,  patients  were  not  ran-
omly  assigned  to  the  two  groups  so  it  was  not  possible  to
ule  out  selection  bias  or  deﬁne  a  true  control  group.  Com-
arison  of  patient  characteristics  in  the  two  groups  revealed
ifferences  in  age  proﬁle,  incidence  of  atrial  ﬁbrillation,
roportion  of  single  chamber  and  CRT  ICDs  and  numbers  of
orin® ICDs  used  because  SmartviewTM RM  was  not  avail-
ble  at  the  time  of  study,  so  no-one  with  this  brand  of
CD  could  be  included  in  the  RM  group.  All  other  patient
haracteristics  were  found  to  be  comparable.  Follow-up
uration  was  noted  to  be  longer  in  the  HO  group  than  the
M  group.  This  was  because  HO  follow-up  began  at  the
ime  of  ICD  implantation  and  RM  follow-up  began  at  RM
ctivation,  which  in  some  cases  may  have  been  after  sev-
ral  years  of  HO  follow-up.  We  have  therefore  reported
esults  in  units  of  consultations/patient/year  to  allow  a
ore  accurate  comparison  to  be  made  between  the  two
roups  although  we  note  that  bias  related  to  this  discrepancy
ay  still  be  present.  Another  important  limitation  resulting
rom  the  retrospective  study  design  was  that  in  46%  of  cases,
t  was  not  possible  to  ascertain  the  time  between  onset
f  asymptomatic  clinical  events  and  time  at  which  clinical
ecisions  were  made.  The  majority  of  these  cases  were  for
atients  who  sustained  supraventricular  arrhythmias  rather
han  more  serious  events  such  as  lead  dysfunction  and  as
uch  there  is  potentially  an  under-representation  of  less
erious  events  in  our  results.
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Several  patients  included  in  our  study  also  participated
in  other  studies,  which  may  have  had  ramiﬁcations  for  how
they  were  managed.  For  instance,  32  patients  in  the  RM
group  and  13  in  the  HO  group  were  included  in  the  EVATEL
trial  and  1  patient  had  previously  been  included  in  the  RM
arm  of  the  ECOST  study.
Further  bias  may  also  be  present  in  our  data  as  a  result
of  delays  in  RM  activation  following  ICD  implantation.  These
delays  were  for  a  number  of  reasons.  For  instance,  the  deci-
sion  to  activate  RM  was  at  the  discretion  of  the  treating
clinician,  which  may  have  introduced  a  delay  in  some  cases.
Twenty-three  patients  were  implanted  with  an  ICD  prior  to
2009  and  waited  until  this  date  for  RM  activation.  Patients
included  in  the  standard  care  arms  of  the  aforementioned
EVATEL  trial  would  also  not  have  been  activated  for  RM  until
after  the  end  of  this  trial.  Delays  may  also  have  arisen  from
logistical  problems  relating  to  the  installation  of  transmit-
ters  in  patient  homes.  Any  of  these  delays  in  RM  activation
may  have  introduced  bias  into  our  results  since  events  like
lead  dysfunction  may  have  a  higher  incidence  immediately
following  ICD  implantation.  We  did  note,  however,  that  only
2  patients  in  the  RM  group  had  urgent  unscheduled  consulta-
tions  prior  to  RM  activation  in  2009  so  we  would  only  expect
this  to  have  a  small  effect.  Also,  79  patients  (55%)  in  the  RM
group  also  had  at  least  one  ambulatory  follow-up  prior  to
RM  activation.
Conclusions
Remote  monitoring  of  ICD  recipients  signiﬁcantly  reduces
the  time  from  onset  of  asymptomatic  events  to  clinical
intervention,  and  therefore  reduces  risk  to  patients  in
potentially  harmful  situations.  RM  also  results  in  a  signiﬁcant
reduction  in  the  number  of  ambulatory  follow-up  consulta-
tions  without  signiﬁcantly  increasing  the  number  of  urgent
unscheduled  consultations,  which  potentially  reduces  the
time-burden  on  clinicians  without  compromising  patient
safety.  In  our  study,  the  vast  majority  of  scheduled  ambu-
latory  consultations  appeared  to  be  unnecessary  from  a
clinical  standpoint,  as  they  did  not  result  in  any  change  of
medication  regime  or  reprogramming  of  the  ICD.  This  sug-
gests  that  with  better  ﬁltering  of  RM  notiﬁcations,  few  of
which  are  clinically  relevant,  further  reductions  in  the  num-
ber  of  ambulatory  follow-up  consultations  may  be  possible.
These  results  therefore  supports  the  use  of  remote  monitor-
ing  for  managing  ICD  recipients  in  daily  clinical  practice.
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